| 7551 | Humans |
| 5230 | Male |
| 4847 | Female |
| 3909 | Middle Aged |
| 3346 | Aged |
| 2531 | Adult |
| 960 | Severity of Illness Index |
| 945 | Aged, 80 and over |
| 940 | Parkinson Disease (drug therapy) |
| 835 | Parkinson Disease (physiopathology) |
| 796 | Parkinson Disease (complications) |
| 736 | Magnetic Resonance Imaging |
| 644 | Parkinson Disease (diagnosis) |
| 592 | Antiparkinson Agents (therapeutic use) |
| 572 | Treatment Outcome |
| 560 | Adolescent |
| 543 | Animals |
| 542 | Neurologic Examination |
| 529 | Levodopa (therapeutic use) |
| 476 | Brain (pathology) |
| 467 | Follow-Up Studies |
| 456 | Diagnosis, Differential |
| 445 | Neuropsychological Tests |
| 411 | Parkinson Disease (pathology) |
| 409 | Parkinson Disease (genetics) |
| 384 | Parkinson Disease (epidemiology) |
| 381 | Case-Control Studies |
| 376 | Electromyography |
| 373 | Antiparkinson Agents (adverse effects) |
| 368 | Parkinson Disease (therapy) |
| 365 | Levodopa (adverse effects) |
| 354 | Child |
| 342 | Parkinson Disease (psychology) |
| 339 | Disease Progression |
| 332 | Dose-Response Relationship, Drug |
| 328 | Retrospective Studies |
| 327 | Time Factors |
| 320 | Questionnaires |
| 294 | Young Adult |
| 289 | Analysis of Variance |
| 280 | Disability Evaluation |
| 260 | Double-Blind Method |
| 253 | Risk Factors |
| 251 | Age of Onset |
| 250 | Deep Brain Stimulation (methods) |
| 235 | Neurologic Examination (drug effects) |
| 225 | Drug Therapy, Combination |
| 224 | Mutation (genetics) |
| 217 | Reproducibility of Results |
| 214 | Genotype |
| 210 | Brain Mapping |
| 205 | Magnetic Resonance Imaging (methods) |
| 203 | Dystonia (physiopathology) |
| 203 | Dystonia (diagnosis) |
| 200 | Phenotype |
| 196 | Pedigree |
| 196 | Cognition Disorders (etiology) |
| 184 | Videotape Recording |
| 182 | Prospective Studies |
| 181 | Levodopa (administration & dosage) |
| 181 | DNA Mutational Analysis |
| 180 | Tremor (physiopathology) |
| 177 | Dominance, Cerebral (physiology) |
| 175 | Tremor (diagnosis) |
| 174 | Antiparkinson Agents (administration & dosage) |
| 168 | Age Factors |
| 167 | Longitudinal Studies |
| 165 | Tomography, Emission-Computed, Single-Photon |
| 165 | Electroencephalography |
| 164 | Parkinson Disease (metabolism) |
| 164 | Cohort Studies |
| 163 | Prevalence |
| 161 | Quality of Life |
| 161 | Cognition Disorders (diagnosis) |
| 159 | Statistics, Nonparametric |
| 157 | Child, Preschool |
| 155 | Cross-Sectional Studies |
| 152 | Drug Administration Schedule |
| 151 | Reference Values |
| 150 | Movement Disorders (etiology) |
| 149 | Movement Disorders (diagnosis) |
| 148 | Dopamine (metabolism) |
| 147 | Dyskinesia, Drug-Induced (etiology) |
| 146 | Tremor (etiology) |
| 144 | Movement Disorders (physiopathology) |
| 143 | Dopamine Agonists (therapeutic use) |
| 142 | Functional Laterality (physiology) |
| 139 | Disease Models, Animal |
| 139 | Brain (physiopathology) |
| 136 | Psychiatric Status Rating Scales |
| 136 | Parkinson Disease (etiology) |
| 135 | Family Health |
| 134 | Tomography, X-Ray Computed |
| 134 | Substantia Nigra (pathology) |
| 133 | Reaction Time (physiology) |
| 133 | Muscle, Skeletal (physiopathology) |
| 132 | Parkinson Disease (radionuclide imaging) |
| 130 | Psychomotor Performance (physiology) |
| 130 | Brain (metabolism) |
| 129 | Functional Laterality |
| 129 | Dystonia (genetics) |
| 127 | Parkinson Disease (surgery) |
| 124 | Parkinsonian Disorders (genetics) |
| 124 | Dystonia (drug therapy) |
| 121 | Genetic Predisposition to Disease |
| 120 | Dystonia (etiology) |
| 118 | Parkinsonian Disorders (diagnosis) |
| 114 | Electrodes, Implanted |
| 113 | Subthalamic Nucleus (physiology) |
| 113 | Motor Cortex (physiopathology) |
| 113 | Cerebral Cortex (physiopathology) |
| 112 | Myoclonus (physiopathology) |
| 111 | Motor Activity (physiology) |
| 110 | Sensitivity and Specificity |
| 110 | Electromyography (methods) |
| 109 | Huntington Disease (genetics) |
| 105 | Basal Ganglia (pathology) |
| 104 | Mutation |
| 104 | Botulinum Toxins, Type A (therapeutic use) |
| 103 | Mental Status Schedule |
| 102 | Movement (physiology) |
| 101 | Protein-Serine-Threonine Kinases (genetics) |
| 101 | History, 20th Century |
| 100 | Nerve Tissue Proteins (genetics) |
| 100 | Injections, Intramuscular |
| 99 | Point Mutation (genetics) |
| 99 | Parkinsonian Disorders (drug therapy) |
| 99 | Corpus Striatum (pathology) |
| 98 | Statistics as Topic |
| 98 | Parkinson Disease, Secondary (chemically induced) |
| 98 | Image Processing, Computer-Assisted |
| 98 | Cerebral Cortex (pathology) |
| 97 | Posture |
| 96 | Predictive Value of Tests |
| 96 | Pilot Projects |
| 95 | Polysomnography |
| 95 | Dystonic Disorders (physiopathology) |
| 94 | Syndrome |
| 94 | Parkinsonian Disorders (pathology) |
| 94 | Dystonic Disorders (diagnosis) |
| 92 | Dystonic Disorders (genetics) |
| 92 | Activities of Daily Living |
| 91 | Multiple System Atrophy (diagnosis) |
| 91 | Cerebellum (pathology) |
| 90 | Gait Disorders, Neurologic (etiology) |
| 88 | Ubiquitin-Protein Ligases (genetics) |
| 88 | Parkinsonian Disorders (complications) |
| 88 | Basal Ganglia (physiopathology) |
| 87 | Deep Brain Stimulation |
| 87 | Antipsychotic Agents (adverse effects) |
| 86 | Tomography, Emission-Computed |
| 85 | Brain (radionuclide imaging) |
| 84 | Torticollis (drug therapy) |
| 84 | Dyskinesia, Drug-Induced (diagnosis) |
| 84 | Dopamine Agonists (adverse effects) |
| 84 | Anticonvulsants (therapeutic use) |
| 83 | Rats |
| 83 | Corpus Striatum (physiopathology) |
| 82 | Neurons (pathology) |
| 82 | Incidence |
| 81 | Tremor (drug therapy) |
| 81 | Neuromuscular Agents (therapeutic use) |
| 81 | Globus Pallidus (physiopathology) |
| 80 | Sex Factors |
| 80 | Huntington Disease (diagnosis) |
| 80 | Atrophy |
| 80 | Alleles |
| 79 | Huntington Disease (physiopathology) |
| 79 | Huntington Disease (complications) |
| 78 | Radiopharmaceuticals (diagnostic use) |
| 78 | Gene Frequency |
| 78 | Dystonia (complications) |
| 78 | Corpus Striatum (radionuclide imaging) |
| 77 | Torticollis (physiopathology) |
| 77 | Dopamine Agents (therapeutic use) |
| 77 | Corpus Striatum (metabolism) |
| 77 | Botulinum Toxins (therapeutic use) |
| 76 | Posture (physiology) |
| 76 | Positron-Emission Tomography |
| 76 | Parkinsonian Disorders (physiopathology) |
| 75 | Subthalamic Nucleus (physiopathology) |
| 75 | Globus Pallidus (surgery) |
| 75 | Essential Tremor (physiopathology) |
| 75 | Dyskinesia, Drug-Induced (drug therapy) |
| 75 | Chi-Square Distribution |
| 74 | Regression Analysis |
| 74 | Chorea (diagnosis) |
| 74 | Anti-Dyskinesia Agents (therapeutic use) |
| 73 | Myoclonus (diagnosis) |
| 73 | Genetic Predisposition to Disease (genetics) |
| 73 | Evoked Potentials, Motor (physiology) |
| 73 | Essential Tremor (diagnosis) |
| 73 | Dystonia (therapy) |
| 73 | Depression (etiology) |
| 73 | Cross-Over Studies |
| 72 | alpha-Synuclein (genetics) |
| 72 | Supranuclear Palsy, Progressive (diagnosis) |
| 72 | Antipsychotic Agents (therapeutic use) |
| 72 | Antiparkinson Agents (pharmacology) |
| 70 | Multiple System Atrophy (pathology) |
| 70 | Globus Pallidus (pathology) |
| 70 | Chorea (etiology) |
| 70 | Brain (drug effects) |
| 69 | Supranuclear Palsy, Progressive (pathology) |
| 69 | Multiple System Atrophy (physiopathology) |
| 69 | Infant |
| 69 | Electric Stimulation Therapy |
| 68 | alpha-Synuclein (metabolism) |
| 68 | Odds Ratio |
| 67 | Postural Balance (physiology) |
| 67 | Nuclear Proteins (genetics) |
| 67 | Globus Pallidus (physiology) |
| 67 | Drug Combinations |
| 67 | Carbidopa (therapeutic use) |
| 65 | Tremor (genetics) |
| 65 | Torticollis (diagnosis) |
| 65 | Restless Legs Syndrome (diagnosis) |
| 65 | Polymerase Chain Reaction |
| 65 | Myoclonus (etiology) |
| 64 | Motor Activity (drug effects) |
| 64 | Dementia (diagnosis) |
| 64 | Chorea (physiopathology) |
| 63 | Mice |
| 63 | Genetic Testing |
| 63 | Exons (genetics) |
| 63 | Dystonia (pathology) |
| 62 | Tomography, Emission-Computed, Single-Photon (methods) |
| 62 | Muscle, Skeletal (innervation) |
| 62 | Movement Disorders (drug therapy) |
| 62 | Gait (physiology) |
| 62 | Comorbidity |
| 62 | Biomechanical Phenomena |
| 61 | Tropanes (diagnostic use) |
| 61 | Movement Disorders (complications) |
| 61 | Levodopa (pharmacology) |
| 61 | History, 19th Century |
| 61 | Dyskinesias (etiology) |
| 60 | Substantia Nigra (physiopathology) |
| 60 | Putamen (pathology) |
| 60 | Parkinson Disease (blood) |
| 60 | Dystonia (chemically induced) |
| 60 | Dementia (complications) |
| 60 | Carbidopa (administration & dosage) |
| 59 | United States |
| 59 | Neural Pathways (physiopathology) |
| 59 | Motor Skills (physiology) |
| 59 | Dopamine (physiology) |
| 58 | Polymorphism, Genetic (genetics) |
| 58 | Parkinson Disease (rehabilitation) |
| 58 | Electromyography (drug effects) |
| 58 | Electric Stimulation |
| 58 | Deep Brain Stimulation (adverse effects) |
| 58 | Basal Ganglia Diseases (diagnosis) |
| 57 | Neurons (metabolism) |
| 57 | Nerve Degeneration (pathology) |
| 57 | Myoclonus (drug therapy) |
| 57 | Movement Disorders (therapy) |
| 57 | Motor Neurons (physiology) |
| 57 | Attention (physiology) |
| 57 | Atrophy (pathology) |
| 56 | Risk |
| 56 | Polymorphism, Single Nucleotide (genetics) |
| 56 | Parkinson Disease, Secondary (diagnosis) |
| 56 | Parkinson Disease (classification) |
| 56 | Dyskinesia, Drug-Induced (physiopathology) |
| 55 | Neurons (physiology) |
| 55 | Motor Skills (drug effects) |
| 55 | Logistic Models |
| 55 | Fatal Outcome |
| 55 | Corpus Striatum (drug effects) |
| 55 | Combined Modality Therapy |
| 55 | Chorea (genetics) |
| 54 | Neural Inhibition (physiology) |
| 54 | Botulinum Toxins (administration & dosage) |
| 53 | Trinucleotide Repeat Expansion (genetics) |
| 53 | Tremor (complications) |
| 53 | Lewy Bodies (pathology) |
| 53 | Dystonic Disorders (therapy) |
| 53 | Clinical Trials as Topic |
| 53 | Carbidopa (adverse effects) |
| 52 | Tremor (therapy) |
| 52 | Substantia Nigra (drug effects) |
| 52 | Iodine Radioisotopes (diagnostic use) |
| 52 | Brain Stem (physiopathology) |
| 52 | Botulinum Toxins, Type A (administration & dosage) |
| 51 | Reaction Time |
| 51 | Neuroprotective Agents (therapeutic use) |
| 51 | Cognition (physiology) |
| 50 | Walking (physiology) |
| 50 | Stereotaxic Techniques |
| 50 | Randomized Controlled Trials as Topic |
| 50 | Movement Disorders (genetics) |
| 50 | Gait |
| 50 | Frontal Lobe (physiopathology) |
| 50 | Evoked Potentials, Somatosensory (physiology) |
| 50 | Dopamine Agents (adverse effects) |
| 50 | Cognition Disorders (epidemiology) |
| 50 | Cerebellum (physiopathology) |
| 49 | Video Recording |
| 49 | Psychomotor Performance |
| 49 | Fluorodeoxyglucose F18 (diagnostic use) |
| 48 | Supranuclear Palsy, Progressive (physiopathology) |
| 48 | Substantia Nigra (metabolism) |
| 48 | Spinocerebellar Ataxias (genetics) |
| 48 | Restless Legs Syndrome (physiopathology) |
| 48 | Psychometrics |
| 48 | Parkinsonian Disorders (etiology) |
| 48 | Multiple System Atrophy (complications) |
| 48 | Dystonic Disorders (etiology) |
| 47 | Parkinsonian Disorders (epidemiology) |
| 47 | Parkinson Disease, Secondary (physiopathology) |
| 47 | Molecular Chaperones (genetics) |
| 47 | Demography |
| 47 | Basal Ganglia Diseases (physiopathology) |
| 46 | Tourette Syndrome (physiopathology) |
| 46 | ROC Curve |
| 46 | Parkinson Disease (mortality) |
| 46 | Myoclonus (genetics) |
| 46 | Myoclonus (complications) |
| 46 | Movement |
| 46 | Heterozygote Detection |
| 46 | Handwriting |
| 45 | Subthalamic Nucleus (surgery) |
| 45 | Neurologic Examination (statistics & numerical data) |
| 45 | Confidence Intervals |
| 45 | Activities of Daily Living (classification) |
| 44 | Parkinsonian Disorders (radionuclide imaging) |
| 44 | Parkinson Disease, Secondary (drug therapy) |
| 44 | Essential Tremor (epidemiology) |
| 44 | Cognition Disorders (psychology) |
| 43 | Transcranial Magnetic Stimulation |
| 43 | Recurrence |
| 43 | Hand (physiopathology) |
| 43 | Dystonic Disorders (pathology) |
| 43 | Brain Stem (pathology) |
| 42 | Tremor (pathology) |
| 42 | Restless Legs Syndrome (drug therapy) |
| 42 | Receptors, Dopamine (drug effects) |
| 42 | Observer Variation |
| 42 | Linear Models |
| 42 | Health Status |
| 42 | Essential Tremor (genetics) |
| 42 | Chorea (pathology) |
| 42 | Brain (blood supply) |
| 41 | Spinal Cord (physiopathology) |
| 41 | Pain Measurement |
| 41 | Outcome Assessment (Health Care) |
| 40 | Thalamus (surgery) |
| 40 | Sensation Disorders (etiology) |
| 40 | Pons (pathology) |
| 40 | Parkinson Disease (economics) |
| 40 | Nerve Tissue Proteins (metabolism) |
| 40 | Muscle Contraction (physiology) |
| 40 | Huntington Disease (pathology) |
| 40 | Huntington Disease (drug therapy) |
| 40 | Cues |
| 40 | Blinking (physiology) |
| 39 | Thalamus (physiopathology) |
| 39 | Single-Blind Method |
| 39 | Restless Legs Syndrome (epidemiology) |
| 39 | Prognosis |
| 39 | Pain (etiology) |
| 39 | Levodopa (pharmacokinetics) |
| 39 | Indoles (therapeutic use) |
| 39 | Hypokinesia (etiology) |
| 39 | Electric Stimulation (methods) |
| 39 | Dopamine Plasma Membrane Transport Proteins |
| 39 | Administration, Oral |
| 38 | Trinucleotide Repeats (genetics) |
| 38 | Psychomotor Performance (drug effects) |
| 38 | Periodicity |
| 38 | Neurons (drug effects) |
| 38 | Neurologic Examination (methods) |
| 38 | Nerve Tissue Proteins |
| 38 | Mesencephalon (pathology) |
| 38 | Cognition Disorders (complications) |
| 38 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 37 | Spinocerebellar Ataxias (diagnosis) |
| 37 | Signal Processing, Computer-Assisted |
| 37 | Positron-Emission Tomography (methods) |
| 37 | Nerve Net (physiopathology) |
| 37 | Health Surveys |
| 37 | Electroencephalography (methods) |
| 37 | Dopamine Agonists (administration & dosage) |
| 37 | Chromosome Mapping |
| 36 | Quality of Life (psychology) |
| 36 | Parkinson Disease, Secondary (etiology) |
| 36 | Neurodegenerative Diseases (pathology) |
| 36 | Haplotypes |
| 36 | Hallucinations (etiology) |
| 36 | Dystonia Musculorum Deformans (genetics) |
| 36 | DNA-Binding Proteins (genetics) |
| 36 | Chorea (drug therapy) |
| 36 | Chorea (complications) |
| 35 | Parkinsonian Disorders (chemically induced) |
| 35 | Movement Disorders |
| 35 | Hypokinesia (diagnosis) |
| 35 | Glycine (genetics) |
| 35 | Frontal Lobe (pathology) |
| 35 | Essential Tremor (pathology) |
| 35 | Electric Stimulation Therapy (methods) |
| 35 | Dystonic Disorders (complications) |
| 35 | Dementia (pathology) |
| 35 | Dementia (epidemiology) |
| 35 | Cognition Disorders (physiopathology) |
| 35 | Blepharospasm (physiopathology) |
| 34 | Tremor (epidemiology) |
| 34 | Transcranial Magnetic Stimulation (methods) |
| 34 | Subthalamic Nucleus (pathology) |
| 34 | Protein Kinases (genetics) |
| 34 | Neurology (history) |
| 34 | Movement Disorders (pathology) |
| 34 | Motor Activity |
| 34 | Gait Disorders, Neurologic (diagnosis) |
| 34 | Dopamine Plasma Membrane Transport Proteins (metabolism) |
| 34 | Chromosome Disorders |
| 34 | Chromosome Aberrations |
| 33 | Thalamus (pathology) |
| 33 | Receptors, Dopamine (physiology) |
| 33 | Proportional Hazards Models |
| 33 | Parkinson Disease |
| 33 | Parkinson Disease (history) |
| 33 | Olfaction Disorders (etiology) |
| 33 | Myoclonus (pathology) |
| 33 | Movement Disorders (history) |
| 33 | Microelectrodes |
| 33 | History, 21st Century |
| 33 | Depression (diagnosis) |
| 33 | Dementia (etiology) |
| 33 | Databases, Factual (statistics & numerical data) |
| 33 | Cerebral Infarction (physiopathology) |
| 33 | Blepharospasm (drug therapy) |
| 33 | Antiparkinson Agents (pharmacokinetics) |
| 32 | Spinal Cord (pathology) |
| 32 | Somatosensory Cortex (physiopathology) |
| 32 | Serine (genetics) |
| 32 | Pregnancy |
| 32 | Neurodegenerative Diseases (complications) |
| 32 | Lewy Body Disease (pathology) |
| 32 | Hypokinesia (physiopathology) |
| 32 | Heterozygote |
| 32 | Clonazepam (therapeutic use) |
| 32 | Cerebral Infarction (diagnosis) |
| 32 | Apomorphine (administration & dosage) |
| 32 | Acute Disease |
| 31 | tau Proteins (genetics) |
| 31 | Supranuclear Palsy, Progressive (complications) |
| 31 | Substantia Nigra (radionuclide imaging) |
| 31 | Spinocerebellar Degenerations (genetics) |
| 31 | Sleep Disorders (etiology) |
| 31 | Orientation (physiology) |
| 31 | Music |
| 31 | Movement Disorders (psychology) |
| 31 | Leg (physiopathology) |
| 31 | Dystonic Disorders (drug therapy) |
| 31 | Dopamine Agents (administration & dosage) |
| 31 | Arm (physiopathology) |
| 30 | Tourette Syndrome (diagnosis) |
| 30 | Synucleins |
| 30 | Selegiline (therapeutic use) |
| 30 | Pergolide (therapeutic use) |
| 30 | Parkinson Disease (cerebrospinal fluid) |
| 30 | Multivariate Analysis |
| 30 | Membrane Glycoproteins |
| 30 | Injections, Subcutaneous |
| 30 | Huntington Disease (psychology) |
| 30 | Genetic Association Studies |
| 30 | Gait Disorders, Neurologic (physiopathology) |
| 30 | Electromyography (instrumentation) |
| 30 | Dopamine Agonists (pharmacology) |
| 30 | Cerebral Infarction (complications) |
| 30 | Caudate Nucleus (pathology) |
| 30 | Callithrix |
| 30 | Basal Ganglia Diseases (pathology) |
| 30 | Basal Ganglia Diseases (complications) |
| 30 | Autonomic Nervous System Diseases (etiology) |
| 29 | United States (epidemiology) |
| 29 | Rats, Sprague-Dawley |
| 29 | Neurodegenerative Diseases (physiopathology) |
| 29 | Movement Disorders (epidemiology) |
| 29 | Macaca fascicularis |
| 29 | Immunohistochemistry |
| 29 | Genes, Dominant (genetics) |
| 29 | Facial Muscles (physiopathology) |
| 29 | Dyskinesias (diagnosis) |
| 29 | Dementia (genetics) |
| 29 | Cerebellar Ataxia (diagnosis) |
| 29 | Acoustic Stimulation |
| 28 | REM Sleep Behavior Disorder (diagnosis) |
| 28 | Nerve Degeneration (physiology) |
| 28 | Neck Muscles (physiopathology) |
| 28 | Multiple System Atrophy (genetics) |
| 28 | Hand (innervation) |
| 28 | Genes, Dominant |
| 28 | Executive Function (physiology) |
| 28 | Essential Tremor (drug therapy) |
| 28 | Diffusion Magnetic Resonance Imaging |
| 28 | Depression (psychology) |
| 28 | Cross-Cultural Comparison |
| 28 | Chromosome Aberrations (genetics) |
